logo
logo

NAMSA acquires WuXi AppTec's medical device testing operations in the U.S. to strengthen its position in medical technology testing and clinical research

Jan 17, 2025•9 months ago

Acquiring Company

NAMSA

Acquired Company

WuXi AppTec

ShanghaiPharmaceuticalBiotechnologyManufacturing

Description

NAMSA announces the definitive agreement to acquire WuXi AppTec's medical device testing operations in the United States, aiming to expand its range of clinical research and testing solutions for customers. This strategic acquisition aligns with NAMSA's commitment to accelerating innovation in medical technology and supporting sponsors in delivering life-saving medical technology worldwide.

Company Information

Company

NAMSA

About

NAMSA is a world-leading MedTech testing, clinical, and regulatory consulting firm dedicated to accelerating medical device product development. With a deep pool of testing, clinical, and regulatory experts, NAMSA helps medical device sponsors improve healthcare and is committed to enhancing stakeholder value through strategic outsourcing and comprehensive in-house services.

Related People

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed